Skip to main content
. 2019 Aug 13;18(2):575–582. doi: 10.1007/s40200-019-00427-w

Fig. 4.

Fig. 4

The rates of DLX Adverse Drug Reactions (ADR)% and Discontinuation % in the present study and some other studies